Biotech Values

[poorgradstudent]

>Moreover, the company will be in deep doo-doo legally if it turns out they fibbed about the quality of these data.<

I'm not suggesting that DNDN has fibbed in any way. However, they've only described the interim 9902A results as "similar", so I'm not sure anyone could pin them down on it even if they are being coy with the wording.

As for the copyright thing, my angle is more ethical. So I don't think passing out the info from a Lehman report is anything different than passing out a BTM report. They both note that no part of the document can be reproduced in any matter.